Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DuPont/Bunge soy alliance

This article was originally published in The Tan Sheet

Executive Summary

Joint venture Solae will focus on production of specialty proteins including soy concentrates, lecithins and isolates, partners DuPont and agribusiness company Bunge report. Firms anticipate annual revenues of more than $800 mil. for venture. St. Louis-based Solae is expected to launch this spring...

You may also be interested in...



ADM buys Solae’s soy

Decatur, Ill.-based Archer Daniels Midland has purchased Solae's soy isoflavone business, the firms announce Feb. 15. The acquisition includes "an extensive portfolio of U.S. patents, numerous foreign equivalents and pending applications," ADM says. The deal was reached under a settlement in an isoflavone concentrate patent infringement lawsuit Solae filed against ADM in 2003. Solae was created as a joint venture between Dupont and Bunge in January 2003 (1"The Tan Sheet" Jan. 20, 2003, In Brief)...

ADM’s Novasoy, Amerifit’s Estroven Allegedly Infringe Solae Patents

Solae is seeking to permanently enjoin Archer Daniels Midland and Amerifit Nutrition from making, using or selling soy products it believes infringe on certain company-owned patents, according to a June 3 complaint

Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer

Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025.  It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel